Quantum-Si Incorporated QSI
- Market cap
- $172.9M
- P/E
- 0.0×
Follow QSI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 9.88 | 5.33 | 1.72 | 1.12 | 0.61 | 0.95 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 11.88 | 25.00 | 8.31 | 3.90 | 4.14 | 5.77 |
High Price
|
|||
| — | — | — | — | 2 | 153 | 196 | 159 | 143 | 145 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 1 | 3 | 2 |
Revenue
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 45.10% | 52.32% | 47.33% |
Gross Margin
|
|||
| — | — | — | (36) | (37) | (95) | (132) | (96) | (101) | (101) |
EBT
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | (8,868.76%) | (3,301.21%) | (4,157.68%) |
EBT Margin
|
|||
| — | 0 | — | (36) | (37) | (95) | (132) | (96) | (101) | (101) |
Net Income
|
|||
| — | — | — | 1 | 1 | 1 | 12 | 4 | (4) | (4) |
Depreciation
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 |
Revenue/Sh
|
|||
| — | — | — | (6.95) | (6.84) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) |
Earnings/Sh
|
|||
| — | — | — | (5.97) | (6.08) | (0.84) | (0.65) | (0.67) | (0.61) | (0.48) |
Cash Flow/Sh
|
|||
| — | — | — | (0.24) | (0.09) | (0.07) | (0.08) | (0.04) | (0.03) | (0.01) |
Capex/Sh
|
|||
| — | — | — | (6.21) | (6.17) | (0.91) | (0.73) | (0.70) | (0.65) | (0.49) |
Free CF/Sh
|
|||
| — | — | — | 0.00 | (29.82) | 5.99 | 2.58 | 1.92 | 1.50 | 1.11 |
Book Value/Sh
|
|||
| — | — | — | 5 | 5 | 80 | 139 | 141 | 143 | 198 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 265.10 | 126.43 | 89.30 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 1.06 | 1.79 | 0.99 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 26.90 | 57.89 | 22.43 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (0.29) | (1.92) | (0.56) |
EV/FCF
|
|||
| — | — | — | (31) | (33) | (67) | (91) | (94) | (88) | (95) |
Op' Cash Flow
|
|||
| — | — | — | (1) | 0 | (6) | (11) | (5) | (5) | (3) |
Capex
|
|||
| — | — | — | (32) | (33) | (73) | (101) | (99) | (92) | (97) |
FCF
|
|||
| — | — | — | — | 35 | 466 | 342 | 255 | 200 | 153 |
Working Cap'
|
|||
| — | — | — | — | 2 | 7 | 16 | — | — | — |
Total Debt
|
|||
| — | — | — | — | (35) | (464) | (335) | (258) | (210) | (163) |
Net Debt
|
|||
| — | — | — | 0 | (160) | 477 | 359 | 272 | 215 | 220 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (180.40%) | (34.93%) | (29.61%) | (27.83%) | (36.99%) | (41.07%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | (467.74%) | (329.73%) | (500.48%) | (1,166.58%) | (126.60%) |
ROIC
|
|||
| — | — | — | 0.00% | (23.08%) | (59.87%) | (31.69%) | (30.45%) | (41.48%) | (46.52%) |
ROE
|
|||
Quantum-Si Incorporated peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LUCD Lucid Diagnostics Inc. | $170.3M | 0.0× | Compare |
| RXST RxSight, Inc. | $196.7M | 0.0× | Compare |
| QTRX Quanterix Corporation | $150.4M | 0.0× | Compare |
| OWLT Owlet, Inc. | $148.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PROF Profound Medical | $204.6M | 0.0× | Compare |
| STIM Neuronetics, Inc. | $214.9M | 0.0× | Compare |
| INGN Inogen, Inc | $138.8M | 0.0× | Compare |
| ELMD Electromed, Inc. | $233.1M | 20.4× | Compare |
Quantum-Si Incorporated (QSI) key facts
- Quantum-Si Incorporated (QSI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024.
- Quantum-Si Incorporated reported a net loss of $101.3 million, or a loss of $0.51 per share, for fiscal 2025.
- As of September 25, 2026, QSI traded at $0.83, a market capitalization of $172.9 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 113× sales.
- Return on equity was −46.5% and debt-to-equity 0.00.
Quantum-Si Incorporated (QSI) Latest News
15 Sep
Quantum-Si announces detection of 18 amino acids using a developmental sequencing kit on Proteus™. Developmental kit progress advances Quantum-Si's protein sequencing technology and competitive positioning.
20 Aug
Quantum-Si (QSI) released its Q2 2026 earnings call transcript covering financial results and business updates. Earnings call details provide periodic updates that may affect near-term sentiment without major strategic shifts.
14 Aug
Quantum-Si Inc delayed the Proteus launch to Q2 2027. Delaying the Proteus launch to Q2 2027 will significantly hinder Quantum-Si's product rollout and revenue generation.
Quantum-Si Incorporated held its Q2 2026 earnings call covering financial results, operational updates and future outlook. Standard quarterly earnings updates can moderately affect near-term stock sentiment without major strategic shifts.
13 Aug
Quantum-Si Q2 earnings call highlighted financial results, operational updates and strategic outlook for the company. Earnings call updates on financials and strategy can moderately affect near-term stock performance and sentiment.
Quantum-Si reports second quarter 2026 financial results and provides Proteus development update. Quarterly results with development update moderately affect financial perception and near-term sentiment.
10 Jun
Quantum-Si partners with Cell Signaling Technology to advance post-translational modification analysis on the Proteus platform. Partnership targets technology advancement in protein analysis for Quantum-Si.
8 May
Quantum-Si Incorporated summarized its Q1 2026 earnings call, covering financial results, operational updates, and future guidance. Q1 2026 earnings highlights and guidance represent major strategic and financial disclosures likely to shift investor sentiment and company trajectory.
Quantum-Si Incorporated (QSI) released Q1 earnings call highlights detailing financial results, operational progress, and future outlook. Q1 earnings highlights cover financial performance and strategic updates with moderate influence on investor sentiment and trajectory.
7 May
Quantum-Si (QSI) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript reveals key financial performance and strategic outlook directly influencing QSI's trajectory and investor sentiment.
Quantum-Si Incorporated reported first quarter 2026 financial results and highlighted key Proteus™ development milestones. Quarterly financial results paired with Proteus milestones advance core protein sequencing technology, significantly impacting trajectory and investor sentiment.
Quantum-Si Incorporated (QSI) reported a Q1 loss and missed revenue estimates. QSI's Q1 loss and revenue shortfall highlights weaker financial performance with moderate effects on investor sentiment and stock trajectory.
28 Apr
Quantum-Si Incorporated announced successful sequencing on its integrated Proteus™ instruments, demonstrating key functionality of the next-generation protein sequencing platform. Successful Proteus sequencing validates core technology, advancing commercialization and strengthening competitive position in protein sequencing market.
15 Apr
Quantum-Si Incorporated announced two customer posters to be presented at the American Association of Cancer Research (AACR) Annual Meeting, highlighting applications of its protein sequencing technology. Customer posters at AACR provide validation of QSI's technology in oncology research, potentially boosting market sentiment and credibility.
14 Apr
Quantum-Si announced a new manuscript demonstrating the value of its single-molecule protein sequencing technology in identifying new cancer treatment strategies. Manuscript validating core protein sequencing tech for cancer research supports innovation and competitive positioning without guaranteeing immediate revenue or market shifts.
8 Apr
Quantum-Si Incorporated announces first customer samples tested on the Proteus™ prototype system. First customer testing on Proteus prototype validates technology progress and boosts commercialization prospects, significantly enhancing investor sentiment and market trajectory.
6 Apr
Quantum-Si Incorporated announces the start of the Proteus™ Roadshow, a series of events to demonstrate its next-generation protein sequencing technology to potential customers and partners. Launching the Proteus Roadshow marks a major commercialization push for Quantum-Si's flagship protein sequencer, potentially driving customer adoption and revenue growth.
4 Mar
Quantum-Si Incorporated released its Q4 2025 earnings call summary, covering quarterly financial results, operational progress, strategic updates, and forward-looking guidance. Q4 earnings call summaries disclose critical financial metrics, revenue growth, and guidance that significantly influence investor sentiment and stock trajectory.
Quantum-Si Incorporated (QSI) highlighted strategic advances in its Q4 2025 earnings call, including progress in product development and market expansion, while grappling with revenue challenges and missing expectations. Strategic advances offer moderate uplift, but revenue shortfalls limit overall trajectory shift.
3 Mar
Quantum-Si (QSI) released its Q4 2025 earnings call transcript, detailing quarterly financial results, operational updates, and forward-looking guidance. Q4 earnings call reveals financial performance, revenue guidance, and strategic initiatives that significantly influence investor sentiment and stock trajectory.
Quantum-Si Incorporated reported fourth quarter and full-year 2025 financial results. Q4 and full-year 2025 financial results directly impact investor sentiment, stock valuation, and future market performance.
Quantum-Si reported Q4 revenue of $0.3 million, missing estimates but up 50% YoY; full-year revenue $1.2 million. Net loss narrowed to $33.1 million. Launched ProteoVue ET software for protein analysis, expanded Illumina NGS partnership. 2024 revenue guidance $3-4 million, with 250,000 Platinum chips shipped. Shares gained 5% post-call. Q4 revenue growth and optimistic 2024 guidance signal operational progress amid persistent losses, moderately boosting market sentiment without transformative shifts.
13 Feb
Quantum-Si Incorporated announced inducement grants under Nasdaq Listing Rule 5635(c)(4) to certain employees. These grants are part of the company's strategy to attract and retain talent, aligning with its growth objectives in the biotechnology sector. The inducement grants are expected to enhance employee motivation and commitment to the company's long-term goals. Inducement grants can positively influence employee retention and motivation, impacting operational performance.
5 Feb
Quantum-Si Incorporated has released two new manuscripts highlighting the advantages of single-molecule protein sequencing in clinical proteomics and the detection of pathogens and toxins. These studies demonstrate the technology's potential to enhance diagnostic capabilities and improve patient outcomes in various medical applications. The release of new manuscripts showcasing significant advancements in protein sequencing technology is likely to enhance Quantum-Si's competitive positioning and market perception.
22 Dec
Quantum-Si Incorporated has launched its new Version 3 Library Preparation Kit alongside enhancements to its suite of data analysis tools. These advancements aim to improve the efficiency and effectiveness of protein sequencing, positioning the company to better serve its customers in the life sciences sector. The launch of significant product enhancements is likely to impact Quantum-Si's competitive positioning and market performance.
15 Dec
Quantum-Si Incorporated announced inducement grants under Nasdaq Listing Rule 5635(c)(4) to certain employees. These grants are part of the company's strategy to attract and retain talent, aligning with its growth objectives in the biotechnology sector. The inducement grants consist of stock options and restricted stock units, which are intended to incentivize key personnel as the company advances its innovative technologies. Inducement grants may enhance talent retention and operational effectiveness, impacting overall performance moderately.
8 Dec
Quantum-Si Incorporated (QSI) is urged to approach its business growth cautiously amid a challenging market environment. The company is focusing on advancing its protein sequencing technology, which is seen as crucial for its future success. However, analysts express concerns about the sustainability of its growth strategy and the need for careful execution to avoid potential pitfalls. Investors are advised to monitor the company's developments closely as it navigates these challenges. The company's focus on protein sequencing technology may influence its competitive positioning but is not expected to drastically alter its trajectory.
20 Nov
Quantum-Si Incorporated (QSI) showcased significant advancements in its Proteus™ technology and outlined its industry-leading technology pipeline during the Investor & Analyst Day. The event highlighted the company's commitment to innovation in the field of protein sequencing, emphasizing the potential of its proprietary platform to transform biological research and diagnostics. Key developments were presented, indicating progress in product capabilities and strategic direction, which could enhance QSI's competitive positioning in the market. Significant advancements in technology and strategic direction are likely to impact QSI's future performance and investor sentiment.
19 Nov
Quantum-Si Incorporated (QSI) announced plans to showcase advancements in its Proteus™ platform and share insights into its technology pipeline during an upcoming Investor & Analyst Day. The event aims to highlight the company's leadership in the industry and its commitment to innovation. The presentation of significant platform developments and insights into the technology pipeline is likely to influence investor sentiment and the company's strategic direction.
10 Nov
Quantum-Si Incorporated (NASDAQ: QSI) experienced a 21% loss last week, impacting both individual investors, who hold 49% of shares, and institutional investors. This decline raises concerns about the company's market performance and investor sentiment. The significant loss may affect investor confidence and market sentiment, but it is not expected to fundamentally alter the company's long-term trajectory.